# FDA recall D-0621-2020

> **Pacira Pharmaceuticals, Inc.** · Class II · drug recall initiated 2019-11-21.

## Product

EXPAREL, Bupivicaine Liposome Injectable Suspension, 1.3%, 266 mg/20 mL (13 mg/mL), Sterile, 20 mL vial, Rx only, Manufactured by: Pacira Pharmaceuticals, Inc. San Diego, CA 92121. NDC: 65250-266-20,

## Reason for recall

Sub Potent Drug: Out of Specification (OOS)

## Distribution

Distributed Nationwide in the USA

## Key facts

- **Recall number:** D-0621-2020
- **Recalling firm:** Pacira Pharmaceuticals, Inc.
- **Classification:** Class II
- **Product type:** drug
- **Status:** Terminated
- **Initiation date:** 2019-11-21
- **Report date:** 2019-12-11
- **Termination date:** 2020-06-03

- **Voluntary/Mandated:** Voluntary: Firm initiated
- **Location:** San Diego, CA, United States

## Primary source

FDA Enforcement Reports: https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=D-0621-2020

## Citation

> AI Analytics. FDA recall D-0621-2020. Retrieved 2026-06-03 from https://api.ai-analytics.org/recall/D-0621-2020. Source: US FDA. Licensed CC0.

---

*[Dataset catalog](/datasets/) · [FDA recalls dataset](/datasets/fda-recalls) · CC0 1.0*